Towards Healthcare
Aseptic Sampling Market Size, Shares, 7.76% Growth Rate

Aseptic Sampling Market Size to Uptrend USD 2.31 Billion by 2034

The Aseptic Sampling Market is set to grow from $1.10 billion in 2025 to $1.63 billion in 2030. Key drivers include rapid growth in the Asia Pacific region and increased adoption of automated aseptic sampling. The on-line sampling technique and downstream processing application are expected to see the fastest growth, with pharmaceutical & biotechnology companies and CMOs & CROs leading the market.

The global aseptic sampling market was estimated at US$ 0.95 billion in 2023 and is projected to grow to US$ 2.31 billion by 2034, rising at a compound annual growth rate (CAGR) of 7.76% from 2024 to 2034. The growing prevalence of chronic conditions demand for pharmaceuticals and biotechnology products, which increases the usage of aseptic sampling procedures.

Aseptic Sampling Market Revenue 2023 - 2034

Unlock Infinite Advantages: Subscribe to Annual Membership

Major Key Insights of the Aseptic Sampling Market

  • North America dominated the market share by 38.2% in 2023.
  • Asia Pacific is expected to grow at the fastest rate during the forecast period.
  • By type, the manual aseptic sampling segment accounted for the largest aseptic sampling market share in 2023.
  • By type, the automated aseptic sampling segment is anticipated to grow at the fastest CAGR during the forecast period.
  • By technique, the in-line sampling technique segment dominated the market in 2023.
  • By technique, the on-line sampling technique segment is expected to grow at the fastest rate during the forecast period.
  • By application, the downstream processing segment held the dominant share of the market and is estimated to grow at the fastest CAGR during the forecast period.
  • By end-use, the pharmaceutical & biotechnology companies segment held the largest share of the aseptic sampling market in 2023.
  • By end-use, the CMOs & CROs segment is estimated to register the fastest growth during the predicted period.

Aseptic Sampling Market: Health Safety

In order to avoid contaminating or changing the sample or its source, aseptic sampling is the technique of aseptically extracting materials utilized in biopharmaceutical operations for analysis. A need for all makers of sterile drugs is microbiological control. The lowering of bioburden is a noteworthy segment of risk mitigation initiatives. Industry groups like PDA and PIC/S, together with regulatory bodies like the FDA, WHO, and EU GMP, provide advice and suggestions to help businesses make the switch from conventional samples to aseptic sampling systems.

How can AI Improve the Aseptic Sampling Market?

Aseptic sampling benefits greatly from AI as it increases efficiency and precision. Artificial intelligence (AI) can examine samples for microbial growth using image recognition algorithms, reducing human error and guaranteeing aseptic conditions are maintained. AI also helps with real-time sample process monitoring, anomaly detection, and quick modification to avoid contamination. By optimizing sample schedules based on previous data, machine learning algorithms can also cut costs and waste. Artificial Intelligence enhances overall accuracy and dependability by freeing up laboratory workers to concentrate on more intricate and crucial facets of aseptic sampling by automating repetitive procedures.

Top Companies in the Aseptic Sampling Market

  • Danaher Corporation
  • Syntegon
  • W. L. Gore & Associates
  • Merck KGaA
  • SIG
  • Sartorius AG
  • Eppendroff
  • GEA Group
  • KEOFITT A/S
  • Lonza Group
  • Thermo Fisher Scientific
  • Qualitru Sampling Systems

Innovation by Syntegon in the Aseptic Sampling Market

Company Name Syntegon
Headquarters Waiblingen, Germany, Europe
Recent Development In June 2024, the food, medtech, and pharmaceutical sectors rely on Syntegon for processing and packaging solutions. The business has presented its most recent innovation. A proprietary Settle Plate Changer (SPC) for automatic viability monitoring in the aseptic filling procedure is the latest innovation. Syntegon will assist clients in adhering to the most recent Annex 1 for both new and old equipment with this creative approach.

Innovation by SIG in the Aseptic Sampling Market

Company Name SIG
Headquarters Switzerland, Europe
Recent Development In April 2024, the goal of the SIG Prime 55 In-Line Aseptic is to eliminate the requirement for spouted pouches to be pre-sterilized by a third party. It is currently commercially available and was discussed during the 2024 Anuga FoodTec trade show in Cologne, Germany. By applying SIG's decades-long experience in aseptic filling technology with in-line sterilization—a technique that has proven effective in the field of carton packs—to spouted pouches, this innovative filling system advances technical advancement.

Growing Biopharmaceuticals Demand Drives the Aseptic Sampling Market

The medications that are produced and sold have been changing throughout the last few years. Nowadays, there is increased competition in the therapeutic market and a notable amount of customized or focused medicines available for common ailments, as well as those that have traditionally been more challenging to treat. The biopharmaceutical industry is now increasingly more prominent. The rise of the biopharmaceutical market is caused by several causes. Increasing patient demand for better healthcare outcomes and a better patient experience is one of them. Other factors include mergers between large pharmaceutical companies and new regulations that encourage greater cooperation between pharmaceutical manufacturers and healthcare providers. Venture capital firms have also increased their investment in early-stage biotech companies.

Regulatory Compliance Restraint the Aseptic Sampling Market

Every step of the aseptic production process takes place in a clean way that complies with regulatory standards to guarantee the sterility and caliber of pharmaceutical goods. The US Food and Drug Administration (FDA) released the Aseptic Processing Guidelines in 1987. Since then, the FDA has updated the guidelines multiple times to provide more clarity on environmental monitoring techniques, cleanroom and process designs, quality control measures, employee qualification, and production record reviews.

Opportunity: Growing Pharma-Biotech in Developing Countries

The aseptic sampling market is growing as the pharmaceutical and biotechnology companies are growing in developing countries. Not only are the major players establishing themselves in those countries, but new companies are also establishing and contributing to the market’s growth. With a wide range of partners in the public and private sectors, UNIDO has advanced local pharmaceutical production (LPP) in developing nations by offering technical assistance and advising services. As part of a worldwide effort, UNIDO helped "mainstream" LPP as an issue for global development and enhanced the operating environment and technical capabilities of regional producers. UNIDO now has a robust and active network of partners and is recognized as a leading organization on the LPP agenda as a result of this involvement.

The Manual Aseptic Sampling Segment Dominated

By type, the manual aseptic sampling segment accounted for the largest aseptic sampling market share in 2023. Although it may be used for any type of sampling event, manual sampling works best when it comes to base flow sampling in dry weather conditions or as a backup for automation sampling. The main benefit of manual sampling is its ease of use—filling a container with water is not a particularly tough task. One further significant benefit is the cheap cost of equipment. The project cost for manual sampling, according to the cost analysis, is $4,250, or $531.25 per month. Because aseptic manual sampling has a long history in the pharmaceutical and biopharmaceutical sectors, there is expected to be a significant demand for it. The advent of single-use aseptic sampling techniques has helped businesses steer clear of expensive issues like cross-contamination.

The Automated Aseptic Sampling Segment: Fastest-Growing

By type, the automated aseptic sampling segment is anticipated to grow at the fastest CAGR in the aseptic sampling market during the forecast period. Computerized solutions that guarantee resilient quality and enable production continuity to satisfy expanding market needs are commonly used to monitor automated aseptic processing. For automated aseptic processing, robotic operations have also grown to be essential as they give thorough records of every operation and enable intelligent data management. These robotic systems have a number of sensors installed that enable them to quickly identify any drift tendencies or production flaws. Therefore, in order to minimize any possible manufacturing losses and guarantee the constant quality of the finished medicinal products, corrective and preventative actions may be swiftly carried out.

For instance,

  • In April 2022, The MAST® (Modular Automated Sampling Technology) platform was acquired from Lonza by MilliporeSigma, a prominent scientific and technology firm based in the United States and Canada. The acquisition was made by Merck KGaA, Darmstadt, Germany. Designed to enhance bioprocessing capabilities for more economical and efficient drug manufacture, the MAST® platform is an automated aseptic bioreactor sampling system.

The In-line Sampling Technique Segment Dominated

By technique, the in-line sampling technique segment dominated the aseptic sampling market in 2023. Real-time analysis of the material is done throughout the production process by in-line sampling and analysis. Inline devices carry out continuous measurements without obstructing the material's flow since they are incorporated right into the process stream. Instant feedback and the capacity to swiftly modify the procedure in the event that deviations are noticed are two benefits of this. Inline analysis compensates for speed and convenience by introducing a larger risk of contamination. There are limits to the quantity of data that can be extracted from an inline detector, even with the appropriate tools.

Fastest Growing: On-line Sampling Technique Segment

By technique, the on-line sampling technique segment is expected to grow at the fastest rate in the aseptic sampling market during the forecast period. Online sampling and analysis happen concurrently with the process, much like in-line sampling. However, samples are often extracted from the process stream and sent to a nearby analyzer. Online analyses can be run on a continuous basis or on a predetermined schedule. Online measurement, in contrast to offline and at-line procedures, allows for measurement as close to the source as feasible, facilitating quicker analysis and better quality control.

The Downstream Processing Segment Dominated

By application, the downstream processing segment held the dominant share of the aseptic sampling market and is estimated to grow at the fastest CAGR during the forecast period. The goal of downstream processing is to extract the desired product from the bioreactor effluent and bring it up to code. Microbial fermentation and downstream processing (DSP) can both benefit from automated aseptic sampling. Automated aseptic sampling has a lot to offer process development. By using this PAT technology, a sample is extracted from its source without the need for physical labor and is sent straight to an analysis or storage location while preserving a closed, sterile sampling environment. Modality-neutral and modular in design, automated aseptic sampling provides adaptable and scalable solutions for its application. It is also possible to integrate this technique with other PAT technologies, such as Raman spectroscopy, to enhance the validation and calibration of data-driven models.

The Pharmaceutical & Biotechnology Companies Segment Dominated

By end-use, the pharmaceutical & biotechnology companies segment held the largest share of the aseptic sampling market in 2023. As the biopharmaceutical industry has evolved significantly in recent years, so have the validation requirements become more stringent, and the understanding of Quality by Design (QbD) and Process Analytical Technology (PAT) has improved, all making aseptic sampling more necessary. When it comes to collecting samples, closed sampling methods have grown popular and have replaced outdated methods such as using glass vials and Steam In-Place Sterilization (SIP) stainless steel valve sampling. In addition to guaranteeing medication safety and contamination control, regulatory bodies require that drug sampling procedures adhere to pertinent laws.

The CMOs & CROs Segment is Fastest Growing

By end-use, the CMOs & CROs segment is estimated to register the fastest growth in the aseptic sampling market during the predicted period. The development and manufacturing of novel medications may be subject to a long variety of regulations. To guarantee a medication is safe for patients once it is on the market, a number of moving components must come together during the discovery, development, research, review, and production stages. As a result, assistance is frequently sought for the various stages of the creation of pharmaceutical medications. These businesses, also known as CDMOs, CROs, and CMOs, support the pharmaceutical and biotechnology sectors.

Major Pharma & Biotech Players Promote North America’s Growth

Aseptic Sampling Market NA, EU, APAC, LA, MEA Share, 2023 (%)

By region, North America dominated the aseptic sampling market share by 38.2% in 2023. Countries like the U.S. and Canada contribute to the market’s growth in North America. The countries not only have major pharmaceutical and biotechnology market players but also make continuous efforts to promote the pharma-biotech sector through government growth.

Top Pharma Companies in the U.S. Top Biotech Companies in the U.S.
Abbvie Johnson & Johnson Services, Inc.
Astrazeneca Amgen Inc.
Bristrol Myers Squibb Pfizer, Inc.
GSK Abbott Laboratories
Johnson & Johnson Biogen
Merck & Co Bristoll-Myers Squibb
Novartis Gilead Sciences, Inc.
Pfizer NVIDIA Healthcare
Roche Holding Walgreens
Sanofi  

By 2022, biotechnology and biomanufacturing will be utilized in the U.S. to enhance the quality of life for citizens, according to the Department of Energy (DOE). The DOE Office of Science has announced new funding grants totaling about $178 million to support biotechnology and biomanufacturing research projects. To help biotechnology and biomanufacturing reach a position where biorefineries may be commercialized, the DOE's EERE increased its efforts and allocated a total of $120 million.

Since 2019, there has been a notable increase in the Canadian biotech industry due to both foreign and local investment in the life sciences sector. This growth is indicative of investor confidence in the biotech industry's value. $25.9 billion in investments have been made in over 175 Canadian businesses. Recently, Bellus, Inversago Pharma, and Chinook Therapeutics have attracted financing from Canadian life science startups. Although there have been fewer acquisitions globally, 65 investment agreements totaling $12 billion were recorded in the Canadian biotech sector in 2023.

Canadian Biotech Deal Value, 2022-2023 (In Billion Dollars)

Growing Pharma Industry Drives Asia Pacific Market

By region, Asia Pacific is expected to grow at the fastest rate during the forecast period. China, India, Japan, and South Korea are the major contributors to the aseptic sampling market growth. The countries are focusing on the growth of their biotechnology and pharmaceutical industries.

Recent government initiatives in China have given priority to homegrown biotech research. The sector's expansion has benefited substantially from a new national strategy. Between 2013 and 2023, the number of biotech PCT patents awarded to Chinese enterprises increased by almost 720 percent, from 266 to 1,920. Businesses that engage heavily in R&D, such as BeiGene, help the Chinese market expand.

For instance,

  • BeiGene committed CNY 12.8 billion ($1.8 billion) in 2023 and CNY 11.2 billion (about $1.6 billion) in 2022 for research and development funding. The company has spent a total of CNY 49.03 billion ($6.86 billion) on research & development during the last five years. Its operational sales came to CNY 39.66 billion ($5.55 billion) that same year. The primary source of funding for research and development at BeiGene is continuous financing. In 2023, BeiGene invested eight times as much in research and development (R&D) as the industry average, which came to CNY 1.57 billion, or about $216 million.

India's pharmaceutical sector is well-known for producing affordable vaccines and generic medications at a third-place global volume in pharmaceutical manufacture. The Indian pharmaceutical business is a major worldwide player, providing millions of people with low-cost, accessible generic medications. This is evidenced by the fact that India has the greatest number of pharmaceutical facilities outside of the United States approved by the United States Food and Drug Administration (USFDA), as well as a sizable number of plants compliant with the Good Manufacturing Practices (GMP) of the World Health Organization (WHO) and approved by regulatory bodies in other nations, the industry offers lower costs without sacrificing quality.

The pharmaceutical industry in India contributes significantly to the nation's international commerce and has been steadily producing a trade surplus. In 2021–2022, pharmaceutical exports were Rs. 1,74,955 crore (USD 23.5 billion), while total imports came to Rs. 60,060 crore (USD 8.06 billion). This meant that there was a trade surplus of Rs. 1,14,895 crore (USD 15.44 billion).

Indian Pharma Sector Turnover (In Crore)

Recent Developments in the Aseptic Sampling Market

  • In October 2022, for the purpose of aseptic sterile powder (API) sampling, Tema Sinergie developed a novel pharmaceutical isolator. Aseptic sampling of large quantities of sterile active components and handling of big containers were requirements that led to the development of the Aseptic Sampling Isolator (AP-IS Series). This innovative isolation system is made up of two side transfer chambers and a big process chamber that is mainly made for sampling large amounts of sterile powders (API) in an aseptic environment.
  • In January 2022, The OmniTop Sample Tubes Adjustable Volume Sampling System (AVSS), developed by Avantor, a global supplier of goods and services to the life sciences industry, was introduced to lower the risk of contamination and minimize volume loss in bioprocessing operations by empowering technicians to gather the exact amount of media required for routine sampling. The system is intended for use in high-integrity product sampling processes, including final fill operations, cell and gene therapy procedures, and the production of monoclonal antibodies (mAbs). In order to boost processing efficiency, the organization also standardizes the bioprocessing sample procedure.

Segments Covered in the Report

By Type

  • Manual Aseptic Sampling
  • Valves
  • Bags
  • Bottles
  • Other Accessories
  • Automated Aseptic Sampling

By Technique

  • In-line Sampling Technique
  • On-line Sampling Technique
  • Off-line Sampling Technique

By Application

  • Downstream Processing
  • Upstream Processing

By End-use

  • Pharmaceutical & Biotechnology Companies
  • CMOs & CROs
  • Others

By Region

  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Thailands
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • UAE
    • Saudi Arabia
    • Kuwait
  • Insight Code: 5213
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: September 2024
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa has certified the degree of Master’s in Pharmacy in the Pharmaceutical Quality Assurance department from Dr D.Y. Patil College of Pharmacy. Her research is focused on the healthcare industry. She is the author or co-author of four Review Articles, which include Solid dispersion a strategic method for poorly soluble drugs and solubility improvement techniques for poorly soluble drugs, Herbal Drugs Used In Treatment Of Cataracts, Nano sponges And Their Application in Cancer Prevention and Ayurvedic Remedies of Peptic ulcer. She has also published a Research Article on the Formulation and Evaluation of Mucoadhesive Tablets of Miconazole cocrystal which was published in GIS Science Journal Volume 9 Issue 8. Her passion for secondary research and desire to take on the challenge of solving unresolved issues is making her flourish is the in the research sector.

FAQ's

Key portions: The sterile portions of the apparatus utilized in an operation are known as key parts. Bunges, needle hubs, syringe tips, dressing packs, etc., are a few examples. All non-intact skin areas, as well as the insertion or access points for any medical equipment attached to the patient, are considered key sites.

Make use of only sterilized tools and containers. Work quickly while opening sterile sampling containers to prevent environmental pollutants from compromising the equipment or sample. Only allow the sample into sterile sampling containers when they are opened; shut the container right away.

FDA, WHO, National Institutes of Health, Department of Biotechnology, USAID, Department of Pharmaceuticals, UNIDO.